Search | VHL Search Portal

1.

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Kastritis, Efstathios; Palladini, Giovanni; Minnema, Monique C; Wechalekar, Ashutosh D; Jaccard, Arnaud; Lee, Hans C; Sanchorawala, Vaishali; Gibbs, Simon; Mollee, Peter; Venner, Christopher P; Lu, Jin; Schönland, Stefan; Gatt, Moshe E; Suzuki, Kenshi; Kim, Kihyun; Cibeira, M Teresa; Beksac, Meral; Libby, Edward; Valent, Jason; Hungria, Vania; Wong, Sandy W; Rosenzweig, Michael; Bumma, Naresh; Huart, Antoine; Dimopoulos, Meletios A; Bhutani, Divaya; Waxman, Adam J; Goodman, Stacey A; Zonder, Jeffrey A; Lam, Selay; Song, Kevin; Hansen, Timon; Manier, Salomon; Roeloffzen, Wilfried; Jamroziak, Krzysztof; Kwok, Fiona; Shimazaki, Chihiro; Kim, Jin-Seok; Crusoe, Edvan; Ahmadi, Tahamtan; Tran, NamPhuong; Qin, Xiang; Vasey, Sandra Y; Tromp, Brenda; Schecter, Jordan M; Weiss, Brendan M; Zhuang, Sen H; Vermeulen, Jessica; Merlini, Giampaolo; Comenzo, Raymond L.

N Engl J Med ; 385(1): 46-58, 2021 07 01.

Article in English | MEDLINE | ID: mdl-34192431

2.

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.

Buda, Gabriele; Ricci, Deborah; Huang, C Chris; Favis, Reyna; Cohen, Nadine; Zhuang, Sen H; Harousseau, Jean-Luc; Sonneveld, Pieter; Bladé, Joan; Orlowski, Robert Z.

Ann Hematol ; 89(11): 1133-40, 2010 Nov.

Article in English | MEDLINE | ID: mdl-20532504

3.

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.

Bladé, Joan; Sonneveld, Pieter; San Miguel, Jesús F; Sutherland, Heather J; Hajek, Roman; Nagler, Arnon; Spencer, Andrew; Robak, Tadeusz; Cibeira, M Teresa; Zhuang, Sen H; Harousseau, Jean-Luc; Orlowski, Robert Z.

Clin Lymphoma Myeloma ; 8(6): 352-5, 2008 Dec.

Article in English | MEDLINE | ID: mdl-19064400

4.

Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.

Zhuang, Sen H; Hung, Y Elizabeth; Hung, Laura; Robey, Robert W; Sackett, Dan L; Linehan, W Marston; Bates, Susan E; Fojo, Tito; Poruchynsky, Marianne S.

Clin Cancer Res ; 13(24): 7480-6, 2007 Dec 15.

Article in English | MEDLINE | ID: mdl-18094432

5.

Oophorectomy in carriers of BRCA mutations.

Zhuang, Sen H; Leonard, Gregory D; Swain, Sandra M.

N Engl J Med ; 347(13): 1037-40; author reply 1037-40, 2002 Sep 26.

Article in English | MEDLINE | ID: mdl-12324566

6.

Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.

Bladé, Joan; Sonneveld, Pieter; San Miguel, Jesús F; Sutherland, Heather J; Hajek, Roman; Nagler, Arnon; Spencer, Andrew; Robak, Tadeusz; Lantz, Keith C; Zhuang, Sen H; Harousseau, Jean-Luc; Orlowski, Robert Z.

Clin Lymphoma Myeloma Leuk ; 11(1): 44-9, 2011 Feb.

Article in English | MEDLINE | ID: mdl-21454189

7.

Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.

Leonard, Gregory D; Zhuang, Sen H; Grem, Jean L.

J Clin Oncol ; 20(19): 4124-5; author reply 4125-6, 2002 Oct 01.

Article in English | MEDLINE | ID: mdl-12351613

8.

Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.

Zhuang, Sen H; Xiu, Liang; Elsayed, Yusri A.

Cancer J ; 15(5): 395-400, 2009.

Article in English | MEDLINE | ID: mdl-19826359

9.

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.

Sparano, Joseph A; Makhson, Anatoly N; Semiglazov, Vladimir F; Tjulandin, Sergei A; Balashova, Olga I; Bondarenko, Igor N; Bogdanova, Natalia V; Manikhas, George M; Oliynychenko, Gennadiy P; Chatikhine, Valery A; Zhuang, Sen H; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne R.

J Clin Oncol ; 27(27): 4522-9, 2009 Sep 20.

Article in English | MEDLINE | ID: mdl-19687336

10.

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.

Sonneveld, Pieter; Hajek, Roman; Nagler, Arnon; Spencer, Andrew; Bladé, Joan; Robak, Tadeusz; Zhuang, Sen H; Harousseau, Jean-Luc; Orlowski, Robert Z.

Cancer ; 112(7): 1529-37, 2008 Apr 01.

Article in English | MEDLINE | ID: mdl-18300257

11.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Orlowski, Robert Z; Nagler, Arnon; Sonneveld, Pieter; Bladé, Joan; Hajek, Roman; Spencer, Andrew; San Miguel, Jesús; Robak, Tadeusz; Dmoszynska, Anna; Horvath, Noemi; Spicka, Ivan; Sutherland, Heather J; Suvorov, Alexander N; Zhuang, Sen H; Parekh, Trilok; Xiu, Liang; Yuan, Zhilong; Rackoff, Wayne; Harousseau, Jean-Luc.

J Clin Oncol ; 25(25): 3892-901, 2007 Sep 01.

Article in English | MEDLINE | ID: mdl-17679727

12.

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

Zhuang, Sen H; Agrawal, Manish; Edgerly, Maureen; Bakke, Susan; Kotz, Herb; Thambi, Paul; Rutt, Ann; Balis, Frank M; Bates, Susan; Fojo, Tito.

Cancer ; 103(9): 1932-8, 2005 May 01.

Article in English | MEDLINE | ID: mdl-15800893

13.

Prostate cancer metastatic to skin.

Leonard, Gregory D; Zhuang, Sen H; Dahut, William.

Urology ; 61(2): 456-7, 2003 Feb.

Article in English | MEDLINE | ID: mdl-12597969

VHL Search Portal

Information and Knowledge for Health

Config filters

Your selection (0)

Export format:

Export: